Bruce & Co., Inc. Fate Therapeutics Inc Transaction History

Bruce & Co., Inc.

$228 Million
Q4 2024

A detailed history of Bruce & Co., Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Bruce & Co., Inc. holds 350,000 shares of FATE stock, worth $297,500. This represents 0.25% of its overall portfolio holdings.

Number of Shares

350,000

Previous 350,000 -0.0%

Holding current value

$297,500

Previous $1.23 Million 52.9%

% of portfolio

0.25%

Previous 0.51%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $156,000 - $278,500	50,000 Added 16.67%	350,000 $1.23 Million
Q2 2024 Aug 09, 2024	BUY	$3.26 - $7.08 $511,819 - $1.11 Million	157,000 Added 109.79%	300,000 $983,000
Q4 2023 Feb 12, 2024	SELL	$1.65 - $3.94 $94,050 - $224,580	-57,000 Reduced 28.5%	143,000 $534,000
Q1 2023 May 12, 2023	BUY	$4.24 - $11.12 $606,320 - $1.59 Million	143,000 Added 250.88%	200,000 $1.14 Million
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $296,350 - $478,650	-5,000 Reduced 8.06%	57,000 $3.38 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $201,750 - $277,560	-3,000 Reduced 4.62%	62,000 $5.38 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $721,600 - $1.17 Million	-10,000 Reduced 13.33%	65,000 $5.36 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $952,250 - $2.52 Million	-25,000 Reduced 25.0%	75,000 $6.82 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $1.01 Million - $1.76 Million	50,000 Added 100.0%	100,000 $3.43 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $669,500 - $1.04 Million	50,000 New	50,000 $978,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $82.5M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bruce & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bruce & Co., Inc. with notifications on news.

Account